NeuroPace
NeuroPace's revenue rose 25.1% to $100 million in fiscal 2025. Its operating margin was −16.3%, up from −27.1% a year earlier. Free cash flow was −$11 million. It paid out $50 million in dividends and buybacks. The diluted share count rose 12.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What NeuroPace does
NeuroPace is a medical device company that treats epilepsy. Its RNS System is an implanted device that watches the brain's electrical activity, recognizes patterns that come before a seizure and sends small electrical pulses to stop it. Clinicians set up each patient's device. The company says it is the only commercially available device that records continuous brain activity data and lets clinicians check patients remotely.
The RNS System can be marketed in the United States only for adults with drug-resistant focal epilepsy, which is epilepsy that medicines don't control and that starts in one part of the brain. The company says this system is its primary source of revenue. As of December 31, 2025, over 8,000 patients had received the RNS System.
NeuroPace is seeking approval for more uses, which would let it reach more of the people with drug-resistant epilepsy over time.
Its biggest risks, as it describes them
- It relies on one product, the RNS System, which can be marketed only in the U.S. for adults with drug-resistant focal epilepsy.
- If it can't sell the system cost-effectively and win wider acceptance, its sales and growth would suffer.
- Factors outside its control may disrupt manufacturing of the RNS System.
- It may not forecast customer demand accurately.
Income statement
NeuroPace lost money in fiscal 2025: a net loss of $22 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 116 | 77 | 66 | 53 | 61 |
| Debt incl. finance leases | 50 | 53 | 57 | 60 | 59 |
| Net debt (negative means net cash) | −66 | −25 | −10 | 7 | −2 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.7x | 1.5x | 2.8x | 7.4x | 3.1x |
| Interest coverage | −3.2x | −5.4x | −3.2x | −2.5x | −2.2x |
| Current ratio | 14.3x | 8.9x | 5.7x | 5.4x | 5.3x |
| Quick ratio | 13.4x | 8.0x | 5.0x | 4.5x | 4.3x |
Cash flow
Projections
Project NeuroPace's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What NeuroPace says to expect
- Full year 2026: total revenue
Revise total revenue guidance for full year 2026 to between $91 million and $92 million, representing underlying RNS growth of 10% to 11%.
- Full year 2026: non-GAAP operating expenses
Revise full year non-GAAP operating expenses to be between $85 million and $86 million, compared to previous guidance of $90 million to $92 million.
- Full year 2026: adjusted EBITDA
Revise Adjusted EBITDA to be between ($8.5) million and ($9.5) million compared to previous guidance between ($7.5) million to ($8.5) million.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $302,102 of NeuroPace shares on the open market, and 1 insider sold $399,250, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | Huennekens R ScottDirector | Bought | 12,500 | $8.29 | $103,661 | Form 4 |
| Nov 17, 2026 | Joel BeckerChief Executive Officer, Director | Bought | 11,891 | $8.35 | $99,293 | Form 4 |
| Nov 17, 2026 | Patrick F. WilliamsChief Financial Officer | Bought | 11,891 | $8.34 | $99,148 | Form 4 |
| Dec 15, 2025 | Martha MorrellChief Medical Officer | Sold plan | 25,000 | $15.97 | $399,250 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 4 of 9 | 5 of 9 |
| Rule of 40 | 13.3% | −0.7% | 13.8% |
| Altman Z'' | −12.04 | −15.14 | −13.13 |
| Accruals ratio | −11.9% | −9.1% | −10.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 9 | 4 of 9 | 5 of 9 |
Compare
Put NeuroPace side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| NeuroPace | FY25 | 25.1% | −16.3% | −11.3% | −81.8% | — | 5 | |
| Beta Bionics | FY25 | 53.9% | −71.5% | −56.1% | — | — | — | Compare |
| Butterfly Network | FY25 | 19.0% | −88.5% | −16.4% | — | — | — | Compare |
| Sanara MedTech | FY25 | 19.0% | 7.1% | 2.1% | 13.0% | 2.6x | 3 | Compare |
| Kestra Medical Technologies | FY26 | 59.0% | −141.6% | −122.6% | — | — | 4 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 41 | 45 | 46 | 65 | 80 | 100 |
| Revenue growth | — | 9.8% | 0.8% | 43.7% | 22.1% | 25.1% |
| Gross profit | 30 | 33 | 32 | 48 | 59 | 77 |
| Research and development | 16 | 18 | 22 | 21 | 24 | 28 |
| Operating income | −13 | −24 | −41 | −27 | −22 | −16 |
| Net income | −24 | −36 | −47 | −33 | −27 | −22 |
| Diluted EPS (US$) | −117.85 | −2.17 | −1.91 | −1.27 | −0.93 | −0.66 |
| Diluted shares (millions) | 0 | 17 | 25 | 26 | 29 | 33 |
| Cash flow | ||||||
| Cash from operations | −22 | −25 | −37 | −20 | −18 | −11 |
| Capital expenditure | 0 | 0 | 1 | 0 | 0 | 0 |
| Free cash flow | −22 | −25 | −37 | −20 | −18 | −11 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 50 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 4 | 8 | 10 | 10 | 11 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 38 | 116 | 77 | 66 | 53 | 61 |
| Debt incl. finance leases | 53 | 50 | 53 | 57 | 60 | 59 |
| Total assets | 56 | 134 | 114 | 108 | 95 | 106 |
| Total liabilities | 62 | 60 | 79 | 87 | 87 | 86 |
| Shareholders' equity | −148 | 74 | 35 | 21 | 8 | 19 |
| Margins and ratios | ||||||
| Gross margin | 73.6% | 74.0% | 71.4% | 73.6% | 73.9% | 77.2% |
| Operating margin | −31.7% | −52.5% | −89.6% | −41.5% | −27.1% | −16.3% |
| Net margin | −59.0% | −79.8% | −103.4% | −50.4% | −34.0% | −21.5% |
| Free cash flow margin | −52.7% | −55.2% | −82.3% | −30.4% | −22.9% | −11.3% |
| Rule of 40 (growth + FCF margin) | — | −45.4% | −81.6% | 13.3% | −0.7% | 13.8% |
| Return on capital | — | — | — | — | −132.5% | −81.8% |
| Return on equity | — | — | −87.0% | −118.9% | −189.3% | −158.7% |
| Return on assets | — | −38.1% | −38.0% | −29.7% | −26.8% | −21.4% |
| Net debt to EBITDA | — | — | — | — | — | — |